Abstract:
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
Abstract:
The present description relates to substituted polycyclic compounds and forms and pharmaceutical compositions thereof and methods of using such compounds, forms or compositions thereof for treating or ameliorating Neisseria gonorrhoeae and Neisseria meningiditis. The present description relates to a compound of Formula (I), Formula (II), Formula (III) or Formula (IV): wherein the dashed line "----- " represents an optional double bond and R1, R2, R5, X and Z are as defined herein, and forms and compositions thereof, and also relates to uses of a compound of Formula (I), Formula (II), Formula (III) or Formula (IV) or a form thereof and methods for treating or ameliorating Neisseria gonorrhoeae (N. gonorrhoeae) or Neisseria meningitidis (N. meningitidis) in a subject in need thereof, comprising, administering an effective amount of the compound to the subject.
Abstract:
The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.
Abstract:
Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
Abstract:
The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.
Abstract:
La presente invención se refiere a compuestos que son útiles como inhibidores de la ruta del inflamasoma de proteína receptora 3 de tipo NOD (NLRP3), procesos para la preparación de dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos, métodos de uso de dichos compuestos en el tratamiento de diversas enfermedades y trastornos, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por NLRP3.
Abstract:
The present invention relates to compounds that are useful as inhibitors of NOD-like receptor protein 3 (NLRP3) inflammasome pathway, processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods of using said compounds in the treatment of various diseases and disorders, and medicaments containing them, and their use in diseases and disorders mediated by NLRP3.